La Chaux-de-Fonds, Switzerland, June 12, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the therapeutic potential of its novel, dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, RP6530, in T-cell Lymphomas, at the 18th Congress of the European Hematology Association (EHA) 2013, to be held from June 13-16, at Stockholm, Sweden.
PI3K delta and gamma isoforms are known to contribute to the development, maintenance, transformation, and proliferation of immune cells. The high level expression of these isoforms in hematopoietic cells including the T & B lymphocytes, monocytes, macrophages and neutrophils, makes dual targeting of PI3K delta and gamma, a promising approach for the treatment of lymphomas.
RP6530 is a potent, selective, and orally active inhibitor of PI3K delta/gamma isoforms with an impressive activity against several cell types representative of various leukemias/lymphomas. RP6530 is poised to enter clinical development in Q3 2013.
Details of the presentation:
- Abstract: "Therapeutic potential of dual PI3K Delta/Gamma inhibition in T-cell Lymphomas" (Abstract code: P985)
- Time and Location- 15 June 2013 between 5.45PM-7PM at the Poster Discussion Session for Novel therapeutics, targeted therapies and gene therapy at the Poster Hall in Stockholmsmässan (Stockholm International Fairs), Stockholm, Sweden.
About Rhizen Pharmaceuticals SA:
Rhizen is a biopharmaceutical company focused on the discovery and development of novel therapeutics targeted to treat cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website (www.rhizen.com).
CONTACT: Anusha Gottumukkala E-mail: email@example.com Source:Rhizen Pharmceuticals SA